Stock Analiz

Taysha Gene Therapies, Inc. (TSHA) financials: revenue, earnings and cash flow

Fiscal 2020–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Net income in fiscal 2025 was -$109M, a net margin of -1115.3%; the best year in this period was 2020 with -$60M.

Over the twelve months to September 30, 2026, revenue was $5M and net income -$156M.

Free cash flow was -$94M in fiscal 2025 and positive in 0 of the 6 years shown.

The diluted share count rose 1710% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2022: $3M20222023: $15M20232024: $8M20242025: $10M2025$10M
Net income
2020: -$60M20202021: -$175M20212022: -$166M20222023: -$112M20232024: -$89M20242025: -$109M2025-$109M
Free cash flow
2020: -$31M20202021: -$132M20212022: -$109M20222023: -$77M20232024: -$82M20242025: -$94M2025-$94M
EPS (diluted)
2020: $-3.4020202021: $-4.6420212022: $-3.7820222023: $-0.9620232024: $-0.3620242025: $-0.342025$-0.34

Income statement

Fiscal yearTTM202520242023202220212020
Revenue$5M$10M$8M$15M$3M——
Gross profit———————
Operating income-$161M-$110M-$91M-$72M-$162M-$173M-$43M
Net income-$156M-$109M-$89M-$112M-$166M-$175M-$60M
EPS (diluted)$-0.43$-0.34$-0.36$-0.96$-3.78$-4.64$-3.40
R&D$126M$86M$66M$57M$91M$132M$32M
Revenue growth—+17.3%−46.1%+517.6%———

Cash flow

Fiscal yearTTM202520242023202220212020
Operating cash flow-$141M-$93M-$81M-$73M-$88M-$117M-$31M
Capital spending-$716000-$738000-$374000-$4M-$21M-$15M-$82000
Free cash flow-$142M-$94M-$82M-$77M-$109M-$132M-$31M
Dividends paid—$0$0$0$0$0$0
Buybacks———————
Stock-based pay$21M$13M$13M$8M$18M$18M$3M

Balance sheet

Fiscal yearTTM202520242023202220212020
Cash—$320M$139M$144M$88M$149M$251M
Debt—$70M$63M$61M$60M$37M—
Equity—$247M$72M$75M$949000$95M$251M
Total assets—$343M$160M$173M$126M$214M$259M
Shares (diluted)406M320M250M116M44M38M18M

Margins and returns

Fiscal yearTTM202520242023202220212020
Gross margin———————
Operating margin-2935.4%-1130.7%-1097.5%-468.8%-6492.7%——
Net margin-2844.6%-1115.3%-1071.6%-722.1%-6635.3%——
FCF margin-2582.6%-960.1%-979.2%-497.6%-4356.9%——
ROIC—-27.6%-53.8%-42.2%-211.9%-103.2%-13.5%
ROE—-44.1%-124.8%-148.9%-17493.6%-183.0%-23.9%

Frequently asked questions

What is Taysha Gene Therapies’s annual revenue?

$10M in fiscal 2025 and $5M over the twelve months to September 30, 2026.

How much profit does Taysha Gene Therapies make?

Net income was -$109M in fiscal 2025 (net margin -1115.3%).

Is Taysha Gene Therapies’s revenue growing?

Yes: revenue rose 17.3% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.